Invex Therapeutics Limited

Invex Therapeutics Limited is a biopharmaceutical company focused on developing treatments for neurological conditions associated with raised intracranial pressure, such as idiopathic intracranial hypertension, traumatic brain injury, and acute stroke. The company specializes in repurposing Exenatide, an already approved drug, which it has trademarked as Presendin™. Invex Therapeutics is dedicated to addressing significant unmet medical needs in neurology through innovative research and clinical development. Listed on the CHI-X Market Australia – Limit Venue, Invex Therapeutics operates within the pharmaceuticals and biotechnology sector, contributing to advancements in neurological care and offering investors exposure to early-stage biotech innovation.